These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 27036356

  • 1. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH, Outterson K.
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [Abstract] [Full Text] [Related]

  • 2. Repairing the broken market for antibiotic innovation.
    Outterson K, Powers JH, Daniel GW, McClellan MB.
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS, Outterson K.
    Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
    [Abstract] [Full Text] [Related]

  • 6. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH, Mohr JF.
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [Abstract] [Full Text] [Related]

  • 7. Overcoming the current deadlock in antibiotic research.
    Schäberle TF, Hack IM.
    Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
    [Abstract] [Full Text] [Related]

  • 8. Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.
    Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen JA.
    PLoS Med; 2016 Jun; 13(6):e1002043. PubMed ID: 27299990
    [Abstract] [Full Text] [Related]

  • 9. Antibiotic research and development: business as usual?
    Harbarth S, Theuretzbacher U, Hackett J, DRIVE-AB consortium.
    J Antimicrob Chemother; 2015 Jun; 70(6):1604-7. PubMed ID: 25673635
    [Abstract] [Full Text] [Related]

  • 10. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B, Bartlett J, Wunderink R, Gilbert DN.
    Am J Respir Crit Care Med; 2015 Jan 15; 191(2):135-40. PubMed ID: 25590154
    [Abstract] [Full Text] [Related]

  • 11. Drug development: Time for teamwork.
    May M.
    Nature; 2014 May 01; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract] [Full Text] [Related]

  • 12. Is the GAIN Act a turning point in new antibiotic discovery?
    Brown ED.
    Can J Microbiol; 2013 Mar 01; 59(3):153-6. PubMed ID: 23540332
    [Abstract] [Full Text] [Related]

  • 13. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development.
    J Antimicrob Chemother; 2011 Sep 01; 66(9):1948-53. PubMed ID: 21700625
    [Abstract] [Full Text] [Related]

  • 14. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM, Mossialos E.
    Soc Sci Med; 2016 Feb 01; 151():167-72. PubMed ID: 26808335
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.
    Lum K, Bhatti T, Holland S, Guthrie M, Sassman S.
    J Law Med Ethics; 2018 Jun 01; 46(1_suppl):66-74. PubMed ID: 30146960
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M, Mossialos E.
    Expert Opin Drug Discov; 2018 Oct 01; 13(10):889-892. PubMed ID: 30175625
    [No Abstract] [Full Text] [Related]

  • 19. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K, McDonnell A.
    Health Aff (Millwood); 2016 May 01; 35(5):784-90. PubMed ID: 27140983
    [Abstract] [Full Text] [Related]

  • 20. Towards new business models for R&D for novel antibiotics.
    So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, Outterson K, Paccaud JP, Payne DJ, Peeling RW, Spigelman M, Weigelt J.
    Drug Resist Updat; 2011 Apr 01; 14(2):88-94. PubMed ID: 21439891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.